Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01141712 · ClinicalTrials.gov registry record · Phase 2
Autologous Transplant in HIV Patients (BMT CTN 0803)
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT01141712 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 43 participants.
The verdict
NCT01141712, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study is a Phase II, multicenter trial assessing overall survival after autologous hematopoietic stem cell transplantation using a BEAM transplant regimen (carmustine, etoposide, cytarabine, melphalan) in lymphoma patients with HIV.
Interventions
- DRUG Melphalan
- DRUG Etoposide
- DRUG Cytarabine
- DRUG BCNU
- PROCEDURE Autologous transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2010-04 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01141712
The ClinicalTrials.gov registry entry for NCT01141712 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT01141712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01141712 about?
NCT01141712 is a clinical study titled "Autologous Transplant in HIV Patients (BMT CTN 0803)". This study is a Phase II, multicenter trial assessing overall survival after autologous hematopoietic stem cell transplantation using a BEAM transplant regimen (carmustine, etoposide, cytarabine, melphalan) in lymphoma patients with HIV.
What is the current status of trial NCT01141712?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2010-04. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01141712?
The interventions under investigation include: Melphalan (DRUG), Etoposide (DRUG), Cytarabine (DRUG), BCNU (DRUG), Autologous transplant (PROCEDURE).
Who is sponsoring clinical trial NCT01141712?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.